ALLMedicine™ Mustard Gas Center
Research & Reviews 59 results
https://doi.org/10.1177/14782715231162675
The Journal of the Royal College of Physicians of Edinburgh; Beaven R
Mar 18th, 2023 - The fruit fly, Drosophila melanogaster, is a simple and powerful model organism. It has played a critical role over more than a century, for example in establishing the field of genetics, and in foundational insights into the molecular basis of de...
https://doi.org/10.1016/j.pharmthera.2023.108366
Pharmacology & Therapeutics; Idle JR, Beyoğlu D
Feb 27th, 2023 - In this review we trace the passage of fundamental ideas through 20th century cancer research that began with observations on mustard gas toxicity in World War I. The transmutation of these ideas across scientific and national boundaries, was chan...
https://doi.org/10.1097/ICO.0000000000003199
Cornea Karimian F, Hassanpour K
Feb 3rd, 2023 - The purpose of this study was to present a novel surgical technique combining 360-degree keratolimbal allograft (KLAL) and simultaneous central keratoplasty termed en bloc KLAL with the central penetrating keratoplasty (PKP) performed in those cas...
https://doi.org/10.1097/ICO.0000000000003182
Cornea Soleimani M, Momenaei B et. al.
Feb 3rd, 2023 - Mustard gas (MG) is a potent blistering and alkylating agent that has been used for military and terrorism purposes. Ocular surface injuries are common after exposure to MG. This review provides an update on the pathophysiology, ocular surface com...
https://doi.org/10.1186/s12890-022-02282-7
BMC Pulmonary Medicine; Kavousi S, Akbarialiabad H et. al.
Dec 21st, 2022 - Respiratory diseases are the leading cause of morbidity and mortality in the survivors exposed to Sulfur Mustard (SM). The late abnormalities can be present as chronic bronchitis, tracheobronchial stenosis, asthma, bronchiectasis, airway narrowing...
Clinicaltrials.gov 3 results
https://clinicaltrials.gov/ct2/show/NCT02192918
May 6th, 2015 - Melanoma is the second most common cancer diagnosed in young women and is responsible for nearly 8,000 US deaths per year. Exposure to ultraviolet radiation (UVR) increases risk for melanoma. The International Agency for Research on Cancer assigne...
https://clinicaltrials.gov/ct2/show/NCT00642447
Mar 25th, 2008 - to assess the effect of Heliox with Noninvasive positive pressure ventilation to decrease dyspnea and improve physiologic and respiratory measures in patients with a previous exposure to Sulfur Mustard gas.
https://clinicaltrials.gov/ct2/show/NCT00512811
Aug 8th, 2007 - to assess the efficacy of inhaled furosemide in mustard gas exposed patients with acute respiratory failure
News 13 results
https://www.onclive.com/view/the-40-year-war
Dec 5th, 2020 - It was 40 years ago in January that Richard Nixon, still grappling with the Vietnam War and not yet overwhelmed by scandal, stood before Congress to deliver the State of the Union address and declared a bold new goal for the nation. The federal ...
https://www.onclive.com/view/from-warfare-to-mainstay-mustard-derivatives-play-evolving-role-in-cancer-therapy
Dec 5th, 2020 - An American soldier demonstrates gas masks for man and horse, circa 1918. Chemotherapy pioneer Jonathan L. Hartwell, PhD, right, at the National Cancer Institute about 1950. Photos courtesy of the National Archives, Bureau of Medicine and Surgery,...
https://www.onclive.com/view/ong_breaking_the_mold
Dec 5th, 2020 - Continuing Medical Education (CME) has now been available online in quantities sufficcient to make the Internet the primary or only CME source for some physicians—for more than 10 years. What was an oddity, and then a paradigm shift, has become th...
https://www.onclive.com/view/per-acquires-expands-chemotherapy-foundation-symposium
Dec 4th, 2020 - Phil Talamo The Chemotherapy Foundation Symposium, one of the largest oncology/hematology-focused conferences in the United States, was acquired last week by Physicians’ Education Resource (PER) Events, LLC, an affiliate of the accredited medical...
https://www.onclive.com/view/cirmtuzumabibrutinib-study-expands-to-include-patients-with-mcl
Dec 4th, 2020 - Hun Ju Lee, MD The phase I/II CIRLL study (NCT03088878), which is evaluating the combination of the monoclonal antibody cirmtuzumab (UC-961) and ibrutinib (Imbruvica), has opened an expansion cohort to include patients with mantle cell lymphoma (...